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ABSTRACT
The introduction of MRI and positron emission
tomography (PET) brain imaging has contributed
significantly to the understanding of different dementia
syndromes. Over the past 20 years these imaging
techniques have been increasingly used for clinical
characterisation and differential diagnosis, and to
provide insight into the effects on functional capacity of
the brain, patterns of spatial distribution of different
dementia syndromes and their natural history and
evolution over time. Brain imaging is also increasingly
used in clinical trials, as part of inclusion criteria and/or
as a surrogate outcome measure. Here we review all the
relatively specific findings that can be identified with
different MRI and PET techniques in each of the most
frequent dementing disorders.
INTRODUCTION
The global prevalence of dementia in 2011 was
estimated to be as high as 24 million, and it is
expected to double every 20 years through to
2040.1 Dementia refers to a spectrum of diseases
that affect the brain causing cognitive and behav-
ioural disturbances. Cognitive problems include dif-
ficulties with memory, attention, language and
other higher cortical functions. Behavioural
changes include, as an example, apathy, aggressive
behaviour, hallucinations and changes in social
interaction. Because of these problems, patients’
ability to relate with the world around them and to
perform the acts of daily life is progressively
affected. All dementia syndromes have relatively
specific imaging findings that can be identified by
one or more imaging techniques, thus contributing
to the differential diagnosis.
Standard structural MRI allows identifying ana-
tomical abnormalities of brain morphology for
both grey and white matter and excluding other
causes of cognitive decline such as the presence of
tumour or hydrocephalus. It is acquired using high-
resolution T1-weighted, T2-weighted and diffusion
tensor imaging (DTI) sequences. T1-weighted MRI
is the preferred modality to examine focal loss of
grey matter volume, usually indicated as atrophy,
which is a common feature of neurodegenerative
dementias (figure 1A, B). It has been shown that
the spatial pattern of grey matter atrophy detected
with T1-weighted MRI parallels the distribution of
pathology specific for different dementia syn-
dromes. As an example, in Alzheimer’s disease
(AD), atrophy parallels the distribution of neurofib-
rillary tangles in the brain.2 3 In addition, the
degree and rate of volume loss are closely corre-
lated with cognitive deficits.4 T2-weighted MRI
sequences including fluid-attenuated inversion
recovery are the preferred modality to examine
white matter and periventricular lesions
characterised by gliosis, ischaemia and oedema
(figure 1C). Therefore, they are particularly useful
in detecting vascular damage including features of
small vessel disease, such as white matter hyperin-
tensities (WMH) (also indicated as leukoaraiosis)
and lacunar infarcts frequently found in vascular
dementia (VaD, see the specific paragraph below),
or other white matter abnormalities typical of rare,
rapidly progressive dementia syndromes (progres-
sive multifocal leukoencephalopathy and leukody-
strophies, not discussed in this review).
Paramagnetic-sensitive MRI sequences such as
T2*-weighted gradient-recalled echo (GRE) or
susceptibility-weighted sequences are most sensitive
to detect microhaemorrhages (figure 1D), which
are common in hypertension-associated VaD and in
cerebral amyloid angiopathy (CAA) (not discussed
in the present review). DTI measures the random
motion of water molecules allowing inferences
about the integrity of white matter tracts. It is cur-
rently used only in research settings to delineate
the structural connectivity and axonal organisation
of the brain.
Functional MRI (fMRI) provides information
regarding the brain’s functional status. With blood
oxygen level-dependent (BOLD) fMRI, it is pos-
sible to design activation maps that show which
parts of the brain are engaged when performing a
task (task-related fMRI) or at rest (resting fMRI
(r-fMRI)).5 The r-fMRI easy to be acquired even in
patients with severe cognitive impairment, has been
recently introduced to study large-scale networks
that are coactivated and functionally connected,
named resting state networks6 7 (figure 2). It has
been shown that different networks may be specif-
ically affected by different dementia syndromes,
suggesting a potential role for this technique in the
differential diagnosis of dementias. However, fMRI
(either task-based or resting) is still only used in
research settings to compare groups of patients
relative to healthy controls, and cannot yet be used
to get clinical information from single patients
given the high variability of BOLD response
between subjects,8 and therefore needs further val-
idation before becoming clinically exploitable.
Other types of functional imaging are positron
emission tomography (PET) and single photon
emission CT (SPECT) techniques, which respect-
ively allow to study metabolism and perfusion of
the brain, at rest or during the execution of a task
(activation-based PET or SPECT). They are based
on the usage of radioactive ligands. They provide
patient-specific information that can help with the
differential diagnosis in clinical settings. In add-
ition, in research settings they allow better under-
standing of the molecular and chemical
pathophysiology of the disease. PET imaging is
considered to have higher specificity and sensitivity
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than SPECT in the diagnosis of different dementia syndromes.9
PET allows the quantification of functional markers of neurode-
generation (eg, cerebral glucose metabolism), specific neuro-
pathological aggregates (amyloid and tau) and other potential
factors involved in pathogenesis of different dementia disorders
(eg, neuroinflammation or neurotransmitter systems).
ALZHEIMER’S DISEASE
AD is the most common age-related neurodegenerative disease.
Its earliest symptoms usually include episodic memory loss, fol-
lowed by deficits in language and executive functioning. AD
worsens over time causing progressive impairment in everyday
functioning usually accompanied, in the later stages, by behav-
ioural disturbances. Recently revised diagnostic criteria require
the presence of progressive cognitive dysfunction in one or
more cognitive domains (reported and objectively measured on
testing) and of functional impairment on the ability to perform
daily activities.10 In addition, these criteria also consider, if
available, the presence of abnormal imaging biomarkers (see
below) that can enhance the likelihood that the clinical syn-
drome of dementia is specifically due to AD pathophysiology.
The histopathological hallmarks of AD are amyloid plaques
containing β-amyloid protein (Aβ) and neurofibrillary tangles.11
These abnormalities are primarily localised in the hippocampus,
temporal cortex and nucleus basalis of Meynert.12
Macroscopically, there is atrophy, which can be easily detected
with T1-weighted structural MRI. Despite the central role of Aβ
and its toxic effects in initiating the pathological cascade that
results in AD, the clinical and neuropathological progression of
AD seems to correlate more with the number and spread of
neurofibrillary tangles.11 Neurofibrillary tangles start to deposit
in the entorhinal cortex then expand to the hippocampus and
amygdala and finally to the association cortex. This sequence of
progression is reflected on MRI, which shows that the areas
most early affected by atrophy are the medial temporal lobes
(figure 1A),13 14 which are among the earliest sites of pathologic
involvement,15 followed by atrophy in medial parietal regions
(posterior cingulate and precuneus) and association areas of the
frontal and lateral temporal lobes in the more advanced stages
of the disease.
PET with 18fluorodeoxyglucose (18FDG) in patients with AD
shows a typical pattern of reduced cortical uptake in posterior
and lateral temporal regions, medial parietal regions, particu-
larly in the posterior cingulate gyrus and precuneus and medial
temporal lobes including the hippocampus.16 17 With progres-
sion of the disease, metabolic deficit spreads to prefrontal asso-
ciation areas as well.18 19 FDG hypometabolism parallels
cognitive function and histopathological diagnosis of AD at
autopsy,20 21 and can predict conversion to dementia in the
elderly.22 Despite the fact that FDG-PET correlates well with the
severity of the cognitive impairment,23 it is not specific for AD.
PETwith tracers targeting insoluble fibrillar Aβ (including the
most studied Pittsburgh Compound-B (PiB), and more recently
developed fluorine-18-labelled tracers (florbetaben, florbetapir
and flutemetamol)) shows abnormal uptake in patients with AD.
Areas found to show high uptake are the prefrontal cortex, pre-
cuneus, posterior cingulate cortex, lateral parietal and temporal
cortex and striatum, with relatively lower tracer uptake in
occipital cortex, globus pallidus and thalamus.24 A review by
Johnson et al8 has combined the data from five longitudinal
studies25–29 and has shown that 37% of people with some
memory concern but no dementia (mild cognitive impairment
(MCI)) will progress to AD within 3 years and increased uptake
on amyloid imaging at baseline occurs in about 93% of these
patients with MCI. Indeed, it is thought that, by being a direct
surrogate for Aβ pathology, amyloid PET has the potential to
detect the very beginnings of AD pathophysiology in the asymp-
tomatic, predementia stage. However, whereas FDG-PET and
structural MRI correlate significantly with the severity of cogni-
tive decline, amyloid PETuptake does not increase with the pro-
gression of the disease, suggesting that amyloid deposition is an
early event that triggers other pathological changes that are then
responsible for further clinical progression. As patients develop
AD, the clinical and histological changes accelerate and proceed
independently from amyloid accumulation. Postmortem studies
have shown that neurofibrillary tangles and not Aβ insoluble
plaques more strongly correlate with neurocognitive impair-
ment. For this reason, research teams in different countries are
now focusing on the development of tau tracers for tau PET to
aid with the diagnosis and treatment of AD.30 Tau is a constitu-
ent of microtubules and an alteration in tau phosphorylation
leads to misfolding of microtubules with the formation of
neurofibrillary tangles.
Activation-based PET and task-based fMRI detect changes in
metabolism or blood flow while the subjects is engaged in a
task, showing which parts of the brain are engaged when per-
forming that specific task. As one of the earliest and most dom-
inant symptoms of AD is the impairment of episodic memory, a
number of functional imaging studies have used episodic
memory tasks, demonstrating reduced activation of the medial
temporal regions in patients with AD relative to controls.31 32
Increased prefrontal cortical activity in patients with AD relative
to controls has also been reported,31 32 but less consistently.
More recently, resting fMRI has been used to study the integrity
Figure 1 Structural MRI sequences. (A) T1-weighted MRI image of a patient with Alzheimer’s disease, arrow pointing at right hippocampal
atrophy; (B) T1-weighted MRI image of a patient with semantic dementia, arrow pointing at left temporal pole atrophy; (C) fluid-attenuated
inversion recovery image of a patient with vascular cognitive impairment and features of small vessel disease consisting of periventricular white
matter hyperintensities; (D) T2*-weighted gradient-recalled echo image of a patient with vascular cognitive impairment, arrow pointing at a
microbleed, another feature of small vessel disease.
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of resting state networks. Among them, the default mode
network (DMN, figure 2A), which includes the posterior cingu-
late cortex, the hippocampus, the medial prefrontal cortex and
the lateral parietal regions, has been shown to be specifically dis-
rupted in patients with AD relative to controls.33 34 Other
frontal and frontoparietal networks show increased functional
connectivity in patients with AD relative to controls.34
However, task-based and resting functional imaging remain
research techniques, as they cannot be used at the single-subject
level and still need large validation studies before they can be
translated and used in clinical practice.
MILD COGNITIVE IMPAIRMENT
MCI can be considered a stage in between normal ageing and
dementia.35 Patients with MCI are more at risk of developing
AD and other forms of dementia, thus this condition is also
indicated as prodromal dementia. MCI is suspected when the
patient, an informant or the clinician raise concern regarding
the patient’s cognitive performance, considered to be outside
the normal range of function for the patient’s age and educa-
tional background, but not yet impaired to be considered
dementia.36 It has been calculated that the annual rate of con-
version from MCI to AD ranges between 5%–10%37 and
Figure 2 Spatial maps of resting state networks (RSN) obtained with resting functional MRI from our recent study.32 The three most informative
orthogonal slices for each RSN are shown. (A) Default mode network; (B) ventromedial visual RSN; (C) dorsolateral visual RSN; (D) auditory RSN;
(E) orbitofrontal RSN; (F) left frontoparietal RSN; (G) right frontoparietal RSN.
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41%,38 further confirming the gradual and progressive nature of
AD, where dementia represents the final stage of a series of
pathological changes that have started decades before the onset
of cognitive symptoms. In this process, it has been suggested
that biochemical and imaging biomarkers become abnormal in a
temporal order, reflecting the various stages of the neuropatho-
logical processes in the brain.39
Structural MRI in patients with MCI detects early focal
atrophy relative to healthy controls, especially in the medial
temporal lobe (MTL) (hippocampus and entorhinal cortex) and
also in regions outside MTL, such as the lateral temporal lobes,
the medial parietal lobes and lateral associative parietal
areas.40 41 Several longitudinal studies have shown that struc-
tural MRI can differentiate patients with MCI who will progress
to AD in the near future (converters) from patients with MCI
who will remain stable (non-converters) and that the hippocam-
pus has greater rates of change in converters than non-
converters,42 which increase close to the time of conversion.43
FDG-PET studies44 conducted on patients with MCI have
shown reduced glucose metabolism first in memory-related
areas like the MTL then in temporoparietal cortex, posterior
cingulate and lateral parietal lobes.
Amyloid PET can also be a useful tool for early detection of
the disease, since it has been proven that in the MCI phase
amyloid accumulation has already reached the levels found in
AD.44 Areas with high amyloid uptake are within the dorsolat-
eral and medial frontal cortex, the temporal lobes and lateral
and medial parietal regions.45 Higher levels of amyloid accumu-
lation suggest a higher risk of conversion to AD.46 Some studies
have shown that positivity to amyloid PET in patients with MCI
is associated with a worst performance in memory tasks com-
pared with amyloid-negative MCI.47 However, there are con-
flicting studies on the role of amyloid deposition as a feature of
progression to dementia42 or part of normal ageing.48
Approximately 10–30% of normal ageing patients have positive
amyloid PET findings.43 Despite this, longitudinal studies have
shown that patients with normal cognition at baseline and posi-
tive amyloid PET have higher risk to progress to AD or other
dementia than subjects with negative amyloid PET.49
As for task-based fMRI, patients with MCI show increased
activation of the medial temporal lobes during the execution of
memory tasks.50 This paradoxically increased activation has
been interpreted as reflecting compensation processes engaged
during the MCI phase to counteract the structural damage,
which dissipate in the AD phase when the neuronal loss
becomes more widespread than it can accommodate. However,
we recently showed that the MTL hyperactivation frequently
observed in MCI is non-specific for successful memory perform-
ance, but it also occurs when MCI subjects fail a memory task,
suggesting that it may therefore represent maladaptive or dys-
functional mechanisms of compensation.35
VASCULAR DEMENTIA
The clinical significance of VaD has been recently revived after
several studies showed the increasing contribution of vascular
risk factors to the development of dementia, especially in later
life, and the high prevalence of vascular lesions in postmortem
studies of patients with dementia.51 52 The diagnosis of VaD
involves the presence of significant history of cerebrovascular
pathology and/or cerebrovascular risk factors, assessed clinically
or using neuroimaging techniques. Recently, the definition of
VaD53 has evolved into the clinical concepts of vascular cogni-
tive impairment (VCI)54 or vascular cognitive disorder,55 which
refer to the whole spectrum of conditions in which there is both
cognitive impairment and either clinical evidence of previous
stroke or imaging evidence of vascular brain injury, either in iso-
lation (pure vascular disease) or in association with other path-
ologies (mixed diseases).
T2-weighted structural MRI techniques play an important
role in the detection of vascular abnormalities associated with
VCI. Features of small vessel disease (the most frequent path-
ology found in VaD) including leukoaraiosis or WMH
(figure 1C), microhaemorrhages or microbleeds and lacunar
infarcts56 have all been associated with risk of cognitive
decline.57 WMH have been largely associated with cognitive,
mood, gait and urinary problems in cross-sectional studies58 and
with global functional decline in longitudinal studies.59 In add-
ition, they have been associated with an increased risk of stroke,
cognitive decline (especially in the executive function and pro-
cessing speed domains) and death60 in the general population.
However, it seems that they are not independently associated
with cognitive decline in populations at risk of dementia (ie,
from memory clinics) unless other structural lesions are also
present.61 62 The presence of lacunar infarcts on structural MRI
is associated with immediate and prospective cognitive decline
depending on the number of lacunes63 and their location.64
Silent lacunar infarct (incidentally found on MRI in absence of
clinical history of cerebrovascular events) are detected in 20%
of healthy individuals and associated with increased risk of sub-
sequent stroke and dementia.65 Cerebral microhaemorrhages or
microbleeds, which are small hypointense lesions visible on
paramagnetic-sensitive MRI sequences (figure 1D), are also fea-
tures of small vessel disease and are found in CAA, and also in
cognitively healthy adults. Their number and lobar localisation
have been associated with cognitive dysfunction mainly affecting
executive functions.66 However, their prognostic value on long-
term cognitive outcome remains controversial.67 Lastly, hippo-
campal atrophy detectable with T1-weighted structural MRI is
also seen in patients with VaD/VCI68 and longitudinal studies
have argued that it is the best predictor of poststroke
dementia.69
The predictive value of the above features of small vessel
disease detectable with standard structural MRI is however
limited by the lack of precise correlation with the degree of cog-
nitive impairment,70 and by insufficient specificity for vascular
pathology.71 DTI has been shown to better correlate with cogni-
tive deficits (particularly executive functions),72 supporting the
notion that cognitive dysfunction in the VaD/VCI spectrum is
due to the disruption of subcortical white matter pathways.73
However, it has mainly been used in research settings in com-
parisons between patients with VaD/VCI and healthy controls.
In the context of VaD/VCI, amyloid PET, which has a high
negative predictive value, is used to distinguish pure vascular
from mixed (with both AD and vascular pathology) forms of
dementia. Thus, the absence of amyloid PET uptake in patients
with dementia suggests a pure vascular origin (ie, younger adults
following stroke and with persistent cognitive impairment for
more than 3 months74). However, the division between AD and
VaD based on amyloid and cerebrovascular disease can be an
extreme classification, since the two conditions have a common
pathophysiology. Studies have shown that non-genetic AD is
caused by vascular risk factors and therefore, a clear distinction
is often not possible.75
The fMRI techniques including r-fMRI have not been exten-
sively used in VaD, even in research settings, mainly due to pre-
vious methodological limitations in accounting for the effect of
concomitant structural vascular lesions (WMH, lacunar infarcts
or larger strokes). A few recent studies, however, showed that
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higher volumes of WMH are associated with reduced functional
connectivity and activation of frontal regions.76 77
FRONTOTEMPORAL DEMENTIA
Frontotemporal dementia (FTD) has a higher prevalence than
AD among those aged below 60 years.78 In 1998, Neary et al
described clinical diagnostic criteria for FTD,79 distinguishing
three different variants: behavioural FTD, semantic dementia
(SD) and progressive non-fluent aphasia (PNFA).
The behavioural variant of FTD presents with behavioural
changes including disinhibition, emotional blunting and detach-
ment and alterations in social behaviour. On T1-weighted struc-
tural MRI, patients present focal atrophy in the frontal lobes, in
particular in the medial, dorsolateral and orbitofrontal regions,
compared with both patients with AD and age-matched
controls.80 81
With FDG-PET it is possible to differentiate FTD from AD.
In AD, FDG-PET shows hypometabolism mainly in the parietal
regions bilaterally, whereas in FTD it shows reduced metabolism
in the frontal and temporal regions.
Recent r-fMRI studies have shown that patients with behav-
ioural variant of FTD have decreased functional connectivity in
the salience network, which is thought to be important in social
cognition and includes the anterior cingulate and fronto-insular
regions82 and increased functional connectivity in the DMN,
with a pattern opposite to the one found in patients with AD.
SD and PNFA are aphasic variants of FTD and present
mainly with language disturbances. SD is characterised by fluent
language and severe semantic memory impairment. PNFA by
non-fluent language, agrammatism and apraxia of speech. On
T1-weighted structural MRI, SD is associated with unilateral
and asymmetrical (either left or right) temporal lobe atrophy,
particularly affecting anterior temporal regions and the temporal
pole, with relative preservation of frontal lobe volumes
(figure 1B). PNFA is instead associated with focal atrophy of the
left posterior and inferior frontal regions and left perisylvian
regions.83
FDG-PET in SD demonstrates hypometabolism of the tem-
poral lobes, particularly in the anterior and lateral temporal
regions, and also in the hippocampus and amygdala.84 PNFA
presents with a similar pattern, except that the left side is the
most affected, and the hypometabolism involves more postero-
superior regions of the temporal lobe, and the posterior and
inferior regions of the left frontal lobe.
The r-fMRI studies have shown that SD targets the left tem-
poral polar network, while the PNFA involves mainly the left
frontoparietal network.83 The former type of dementia pre-
sents, therefore, with a reduced connectivity between the
frontal and temporal/limbic areas, but with an increased con-
nectivity in the prefrontal cortex. These findings are supported
by fMRI studies on patients with SD, which have demonstrated
an altered activation during tasks such as sound, autobio-
graphical memory and language tasks. Patients with PNFA, on
the other hand, have reduced activation, on fMRI, during sen-
tence reading and comprehension.84
DEMENTIA WITH LEWY BODIES
Dementia with Lewy bodies (DLB) is defined as a synucleinopa-
thy, since it is formed by insoluble α-synuclein, which aggregates
to form the Lewy bodies (LBs)—the major pathological feature
of DLB. LBs are round eosinophilic inclusions seen microscopic-
ally in cortical and subcortical regions of patients with DLB and
their density correlates with the severity of the disease.85
Clinically, DLB presents with dementia, parkinsonism and visual
hallucinations.86 Other suggestive clinical features comprehend
rapid eye movement sleep behaviour disorders, unexplained
falls and severe neuroleptic sensitivity.86
On T1-weighted structural MRI, patients with DLB show less
typical focal atrophy of the hippocampus and other medial tem-
poral lobe structures relative to patients with AD.87 Structural
MRI studies on patients with DLB have shown a more extensive
atrophy in cortical and subcortical structures such as striatum,
substantia innominata, hypothalamus and dorsal midbrain88
relative to AD or healthy controls. However, at the single-
subject level, focal atrophy and other structural changes, such as
WMH, remain not helpful in the differential diagnosis of DLB
with other types of dementia.
DTI studies showed increased damage in the corpus callosum
and pericallosal areas89 in patients with DLB compared with
controls. In the same way as T1-weighted MRI, the utility of
this technique in supporting a diagnosis of DLB at the single-
subject level still needs to be validated.
PET and SPECT imaging can be helpful to target dopamine
receptors and detect dopamine transporter loss (DaTscan) in the
basal ganglia. If abnormal, it suggests diagnosis of parkinsonism,
allowing to distinguish, as an example, DLB from AD. Decreased
dopamine transport in the caudate is associated with cognitive
symptoms, whereas a reduction in the putamen is associated with
motor symptoms. However, abnormal dopamine transporter
SPECT and PET findings do not allow to distinguish DLB from
other parkinsonism such as idiopathic Parkinson’s disease.
Altered dopamine uptake, together with the lack of atrophy in
the MTL, represents two main features of DLB neuroimaging.90
FDG-PET in patients with DLB show significant hypometabo-
lism in parietal and occipital areas, with relatively preserved
metabolism in the temporal lobes, and with a pattern that is
more ‘posterior’ and different from the one typical of AD.
These features indicate that occipital hypoperfusion is more spe-
cific for DLB.91
DLB is accompanied also by amyloid deposition similarly to
AD. Amyloid PETuptake in patients with DLB is lower than the
one observed in patients with AD, but with a similar anatomical
distribution to AD and there is a higher intersubject variability.92
However, compared with Parkinson’s disease, DLB shows
higher levels of amyloid deposition.93 Moreover, higher levels
of amyloid in patients with DLB are associated with worse cog-
nitive performance.
The r-fMRI studies demonstrated increased functional con-
nectivity between the right posterior cingulate and other regions
of the brain and reduced corticocortical connectivity.94 Finally,
in adherence with occipital hypoperfusion and atrophy neuroi-
maging findings, fMRI studies highlighted reduced activation in
the occipitotemporal lobe during visual tasks such as visual
motion and face matching.94
CONCLUSION
We showed that different MRI and PET imaging techniques can
detect relatively specific abnormalities in each of the most fre-
quent dementia syndromes, and that the recent advent of new
neuroimaging techniques such as resting fMRI, DTI and
amyloid PET has allowed a rapid growth of research into
dementia. However, imaging retains a supportive role in add-
ition to the clinical assessment, and cannot be used in isolation
to reach a diagnosis in people with dementia.
Obvious strengths of MRI are its availability in most Western
countries, relatively low cost and non-invasiveness.95 On
T1-weighted structural MRI, it is very useful to detect focal
atrophy to help differential diagnosis of the different forms
















ed J: first published as 10.1136/postgradm





of neurodegenerative dementia.96 The significant correlation of
atrophy with cognitive decline is indisputable.
Therefore, studies are trying to standardise and validate struc-
tural imaging and in particular hippocampal volumetry so that it
can be adopted for diagnosis and in clinical trials.97 On the
other side, structural MRI limitations comprehend the lack of
specificity for underlying pathology of dementing syndromes, as
atrophy patterns may overlap across different diseases.
Structural MRI, moreover, takes long time to change and does
not provide information about function like fMRI, therefore,
limiting the possibility to detect dynamic, short-term changes in
response to potential treatments. Further studies with advanced
and novel MRI techniques will likely provide more information
about pathology associated with the various dementia diseases.
Strengths of PET are that it targets molecules/receptors (ie,
altered glucose metabolism and amyloid imaging) relevant to
the pathogenesis of different dementia disorders, allowing pre-
clinical diagnosis in presymptomatic individuals and improving
differentiation from other types of dementia. In research set-
tings, it can reveal important aspects of pathogenesis across the
different dementia disorders, with the potential for novel thera-
peutic targeting.
Cost-effectiveness studies98 99 have demonstrated that neuroi-
maging techniques improve diagnosis and quality-adjusted life
years. Evaluation of patients with MRI and/or PET scans can aid
in the diagnosis without additional overall costs, allowing to
increase diagnostic accuracy and to improve quality of life with
the correct management and treatments.
It is also important to mention that if on one side MRI and
PET scans are more widely available and more cost-effective,
often patients cannot tolerate them due to claustrophobia, dis-
comfort or behavioural problems. However, studies have shown
that if subjects are well prepared prior the scanning through
education and training, they are able to tolerate even long MRI
sessions.100
It is expected that in future different neuroimaging techniques
will increasingly be combined in the management of people
with or at risk of dementia with the aim of identifying the pres-
ence of a molecular abnormality, studying its effect on the brain
structure and function, and measuring the effects of new treat-
ments. Studies with more advanced MRI technologies and new
Main messages
▸ Neuroimaging techniques are useful in the diagnosis and
differential diagnosis of different types of dementia and
facilitate the understanding of pathological processes
underlying different dementias.
▸ The main neuroimaging techniques currently used in clinical
settings are structural MRI (to identify atrophy or white
matter lesions) and positron emission tomography (PET) and
single photon emission CT (to study altered metabolism and
hypoperfusion).
▸ In typical Alzheimer’s disease (AD), the first area showing
atrophy or loss of volume is the medial temporal lobe,
followed by medial parietal regions and association areas of
the frontal and lateral temporal lobes.
▸ Amyloid PET uptake is an early biomarker of AD, but does not
increase with the progression of the severity of dementia.
▸ Neuroimaging abnormalities in vascular dementia are
diverse but non-specific. White matter hyperintensities
correlate with cognitive impairment, but are also present in
normal ageing patients.
▸ Frontotemporal dementia and its three main different
subtypes have specific MRI and PET findings with focal
atrophy and hypometabolism localised in frontal and
temporal regions.
Current research questions
▸ What can emerging neuroimaging techniques reveal about
the functional and molecular effects of different types of
dementia?
▸ How can functional MRI improve the differentia diagnosis of
dementia in the single patient?
▸ What are the potentials of resting functional MRI?
Self assessment questions
Please answer True or False to the below statements.
1. Medial temporal lobe (MTL) atrophy is a hallmark biomarker
of Alzheimer’s disease (AD) and it can be detected with
fluorodeoxyglucose positron emission tomography
(FDG-PET).
2. In patients with mild cognitive impairment (MCI), structural
MRI can detect focal atrophy even in areas outside the MTL.
3. Functional MRI is already currently used in a clinical setting
for the differential diagnosis between the different types of
dementia.
4. Leukoaraiosis or white matter hyperintensities (WMH) and
microbleeds are MRI biomarkers highly specific for vascular
dementia.
5. Amyloid deposition is a prerequisite of AD and it can also
be found in other types of dementia.
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PET tracers such as tau will help enable a better understanding
of the pathology of neurodegenerative diseases and may be
applied in clinical trials for the development of disease-
modifying drugs.
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Answers
1. False. MTL atrophy is a hallmark biomarker for AD, however,
atrophy can be investigated mainly with structural MRI,
whereas FDG-PET allows to highlight areas with reduced
18
fluorodeoxyglucose metabolism.
2. True. Structural MRI has shown that patients with MCI can
have similar pathological findings to AD, and so atrophy can
be found also in regions outside MTL, such as the lateral
temporal lobes, the medial parietal lobes and lateral
associative parietal areas.
3. False. fMRI is still used mainly in a research setting as it has
a high variability among individuals and it is still mainly
used to compare group of patients with healthy controls.
4. False. The presence of leukoaraiosis/WMH and microbleeds
indicates higher risk of cognitive decline, stroke and death;
however, these imaging features are not highly specific for
vascular dementia and can be present in the normal ageing
population.
5. True. Amyloid deposition can be found even in other types
of dementia, like dementia with Lewy bodies, and it
correlates with cognitive decline.
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